⚡ Quick Summary
The Cartiva Synthetic Cartilage Implant (SCI), manufactured by Stryker Corporation, was marketed as a breakthrough alternative to big toe fusion surgery. Instead, independent studies found it failed at rates up to 79% within two years — versus the 13% rate used to gain FDA approval. Stryker issued a full recall in October 2024. In February 2026, all federal cases were consolidated into MDL No. 3172 in Arkansas, with the first bellwether trial set for August 2026. Patients who experienced implant failure, revision surgery, or permanent disability may be entitled to $50,000–$1M+ in compensation. Case reviews are 100% free.
Who Qualifies for a Cartiva Lawsuit?
You may be eligible to file a claim if you meet the following criteria:
How the Defect Happened — And Why Stryker Is Liable
Lawsuits allege a years-long pattern of misrepresentation, inadequate testing, and failure to warn — here is how it unfolded:
- 1
FDA approval based on misrepresented failure data — Cartiva Inc. obtained expedited 510(k) FDA approval in 2016 based on a claimed 13% failure rate. Lawsuits allege this figure did not reflect true real-world performance, and that internal data and post-market surveillance showed far higher complication rates.
- 2
Independent studies revealed catastrophic failure rates — Research published as early as 2020 found failure rates of 64%, rising to 79% in studies published in 2025. Patients with Cartiva were found 30 times more likely to require reoperation than those who chose alternative procedures. Despite these published findings, Stryker did not update warnings or issue a recall.
- 3
Deceptive marketing as a fusion-sparing solution — Cartiva was aggressively marketed as a minimally invasive alternative to big toe fusion surgery — the very outcome thousands of patients ultimately required after implant failure. Plaintiffs allege this marketing caused patients to forgo better-established surgical options.
- 4
Stryker acquired Cartiva and continued sales — After acquiring Cartiva Inc. through Wright Medical Group, Stryker continued distributing the implant for years despite mounting evidence of high failure rates, without updating physician or patient warnings.
- 5
Full recall issued October 2024 — years too late — Stryker recalled all Cartiva implants in October 2024, acknowledging "higher-than-expected occurrence rates" of device failures, revisions, and removals. By that time, thousands of patients had already undergone failed implants, revision surgeries, and permanent disability — many having experienced the big toe fusion they originally paid to avoid.
Injuries & Complications Linked to Cartiva Failure
Attorneys are actively investigating the following complications suffered by patients whose Cartiva implants failed:
What Affects Your Cartiva Settlement Value?
Settlement values in the Cartiva MDL will be individualized. Key factors attorneys will evaluate include:
- 🦴
Severity of implant failure — Subsidence, fracture, and migration represent the most serious mechanical failures. Patients who required the implant to be surgically removed typically have stronger claims than those with milder complications.
- 🏥
Number of revision surgeries — Each additional surgery adds medical costs, recovery time, lost wages, and pain and suffering damages. Patients who required multiple procedures carry substantially higher claim values.
- 🚶
Whether fusion surgery was ultimately required — Patients who ended up needing the big toe arthrodesis they originally sought to avoid have a particularly compelling narrative of harm. These cases are expected to yield higher settlement values.
- 📋
Quality of medical documentation — Imaging studies (X-rays, MRIs, CT scans), surgical records, post-operative notes, and physician communications documenting implant failure and complications significantly strengthen your claim.
- 💼
Lost income and reduced earning capacity — Extended recovery from multiple surgeries, or permanent mobility limitations that affect your ability to work, add significant economic damages to your claim.
- 📍
Jurisdiction and implant date — State law affects damage caps and negligence standards. Implants received earlier (2016–2020) may carry stronger claims given the longer period during which Stryker allegedly failed to warn despite mounting evidence.
Filing Deadlines — State Statute of Limitations
Every state imposes strict deadlines for filing medical device injury lawsuits. Missing your deadline permanently bars your claim. The October 2024 recall is a key trigger date — but patients who discovered complications years earlier may face earlier deadlines. Always confirm with an attorney for your specific situation.
| State | SOL for Product Liability | Discovery Rule Applies? |
|---|---|---|
| California | 2 years | Yes — from date of discovery |
| Texas | 2 years | Yes — limited circumstances |
| Florida | 2 years | Yes — from date of discovery |
| New York | 3 years | Yes — from date of discovery |
| Pennsylvania | 2 years | Yes — from date of discovery |
| Illinois | 2 years | Yes — from date of discovery |
| Arkansas (MDL State) | 3 years | Yes — from date of discovery |
| All Other States | 2–4 years (varies) | Consult an attorney |
Cartiva Lawsuit Updates
Last updated: June 2026 — Newest first
February 5, 2026
JPML Approves Cartiva MDL — Eastern District of Arkansas
The U.S. Judicial Panel on Multidistrict Litigation consolidated all federal Cartiva toe implant lawsuits into MDL No. 3172 before Judge Kristine G. Baker in the Eastern District of Arkansas. The JPML rejected Stryker's argument that injuries were too varied for centralization, ruling that common questions of fact exist regarding causation, testing, labeling, FDA representations, and recall circumstances. Five active cases and nine potential tag-along actions from seven districts are now consolidated. The first bellwether trial is scheduled for August 2026.
February 5, 2026
Pennsylvania Woman Files New Lawsuit
A Pennsylvania plaintiff filed suit alleging her Cartiva implant received in 2021 failed within two years, requiring surgical removal and causing continued pain and loss of mobility. The complaint alleges she relied on marketing materials emphasizing long-term pain relief while the manufacturer concealed true failure rates and risks of implant shrinkage and migration.
March 2026
Mediation Sessions Scheduled
Parties selected former U.S. Magistrate Judge Lisa Lenihan to oversee mediation, with the first session scheduled for March 12, 2026. The scheduling of mediation alongside active MDL proceedings signals both sides may be open to settlement negotiations ahead of the August 2026 bellwether trial.
January 27, 2026
Big Toe Fusion Lawsuit Filed
A plaintiff filed suit after requiring arthrodesis (big toe fusion surgery) following Cartiva failure — the very outcome the device was marketed to prevent. The case highlights a documented pattern of patients ultimately requiring the fusion surgery they originally sought to avoid by choosing the Cartiva implant.
November 2025
Multiple Cases Voluntarily Dismissed — Confidential Settlements Suspected
A pattern of voluntary dismissals prompted widespread speculation that Stryker has been reaching confidential settlements with individual plaintiffs to avoid MDL consolidation and public trial outcomes. This mirrors strategies used by medical device manufacturers in other high-profile defective implant litigations.
October 2024
Stryker Issues Full Recall of All Cartiva Implants
Stryker issued a voluntary recall of all Cartiva Synthetic Cartilage Implants sold since July 2016, acknowledging "higher-than-expected occurrence rates" of device failures, revisions, and removals. The recall covers all devices distributed in the United States. Plaintiffs' attorneys immediately filed a petition with the JPML requesting MDL consolidation.
September 2025
Study Confirms 79% Failure Rate; Patients 30x More Likely to Need Reoperation
A major independent study published in 2025 found Cartiva failure rates as high as 79% within two years of implantation, and confirmed patients with Cartiva implants were 30 times more likely to require reoperation than those who underwent alternative procedures. The American College of Foot and Ankle Surgeons confirmed the implant had higher complications than originally reported.
2020–2024
Years of Published Studies Showing Failure Rates of 64–79%
Multiple peer-reviewed studies published between 2020 and 2024 documented Cartiva failure rates of 64% or higher — versus the 13% rate used to gain FDA approval in 2016. Lawsuits allege Stryker continued marketing and selling the device during this period without updating warnings or conducting adequate post-market surveillance to address the mounting evidence of harm.
Cartiva Was Supposed to Help You — It Didn't
If you received a Cartiva implant and suffered failure, revision surgery, or permanent disability, you may be owed significant compensation. Case reviews are completely free with no obligation to hire.
How the Legal Process Works
- 1
Submit your free case review — Provide basic details about your implant procedure and complications. Takes under 3 minutes with no obligation.
- 2
Case evaluation against recall criteria — We review your details against the Cartiva recall and qualifying injury criteria to determine if you may be eligible.
- 3
Connect with a partner attorney — If you may qualify, we connect you with a vetted mass tort attorney experienced in defective medical device litigation.
- 4
Free attorney consultation & medical record review — Your attorney reviews your surgical records, imaging studies, and complication history at no cost. No obligation to proceed.
- 5
Implant preservation (if surgery pending) — If revision surgery is upcoming, your attorney coordinates with the hospital pathology department to properly preserve the removed implant as evidence before the procedure.
- 6
Lawsuit filed & transferred to MDL — Your attorney files your individual product liability claim. Federal cases are transferred to MDL No. 3172 in Arkansas for coordinated pretrial proceedings. No upfront cost — contingency only.
- 7
Bellwether trials & settlement negotiations — Select test cases go to trial starting August 2026 to establish liability and settlement values. Most cases are expected to settle following bellwether outcomes. You decide whether to accept any offer.
- 8
Compensation recovered — If your attorney wins compensation, they receive a contingency percentage (typically 33–40%). If they don't win, you owe nothing.
Frequently Asked Questions
Who qualifies for a Cartiva lawsuit?
You may qualify if you received a Cartiva Synthetic Cartilage Implant in the big toe between 2016 and 2024 and experienced implant failure — including subsidence, loosening, fracture, or migration — resulting in severe pain, loss of mobility, or revision surgery. Patients who ultimately required big toe fusion (arthrodesis) after Cartiva failure are among the strongest candidates for compensation.
How common is Cartiva implant failure?
Cartiva failure is far more common than originally represented. The FDA approved the device in 2016 based on a claimed 13% failure rate, but independent studies published between 2020 and 2025 found failure rates of 64% to 79% within two years. Patients with Cartiva implants were 30 times more likely to require reoperation compared to those who underwent alternative procedures. The American College of Foot and Ankle Surgeons confirmed the implant had higher complications than originally reported.
What is the current status of the Cartiva MDL?
On February 5, 2026, the U.S. Judicial Panel on Multidistrict Litigation consolidated all federal Cartiva lawsuits into MDL No. 3172 before Judge Kristine G. Baker in the Eastern District of Arkansas. The first bellwether trial is scheduled for August 2026. Mediation sessions are also underway as of March 2026, indicating potential parallel settlement negotiations.
How much are Cartiva lawsuit settlements worth?
Settlement values are expected to range from $50,000 to over $1 million per case depending on the severity of complications, number of revision surgeries required, and degree of permanent disability. Higher settlements are anticipated for patients who required multiple surgeries, suffered permanent mobility loss, or ultimately needed the big toe fusion they originally sought to avoid. Law firms handling Cartiva cases have previously secured over $1 billion in settlements against Stryker in other defective implant litigation.
Is there a deadline to file a Cartiva lawsuit?
Yes. Statutes of limitations for medical device claims vary by state but typically range from 2 to 4 years from when you discovered — or reasonably should have discovered — that your complications were caused by the defective implant. The October 2024 recall may serve as a key trigger date for many patients. However, those who experienced documented complications years earlier may face earlier deadlines. Contact an attorney immediately to protect your rights.
Did Stryker know about Cartiva's failure rates and hide them?
Lawsuits allege that Cartiva Inc. and Stryker knew about abnormally high failure rates but failed to warn patients or update FDA labeling. The device was approved based on a 13% failure rate, but peer-reviewed studies published as early as 2020 showed failure rates of 64%. Despite this mounting evidence, Stryker did not issue a recall until October 2024 — years after the problems became publicly documented. Plaintiffs argue that had the FDA known the true failure rates at the time of approval, the device may never have reached patients.
What if I haven't had revision surgery yet but my Cartiva is causing problems?
You may still qualify even without revision surgery. If you are experiencing persistent pain, loss of mobility, or your doctor has recommended removal or revision, consult an attorney immediately. Document all symptoms and keep records of medical appointments and imaging studies. If revision surgery is recommended or scheduled, notify your attorney so they can coordinate with the hospital to properly preserve the removed implant as evidence before the procedure.
